December 11, 2007
Article
Side effect may predict response to treatment.
Getting a rash with a drug that’s targeting the epidermal growth factor receptor (EGFR) may be a sign that it’s killing the tumor.
ICI Response May Predict Relapse-Free Survival in Liver Cancer
Taking Time to ‘Smell the Roses’
Addressing Pros and Cons of CAR-T Cell Therapy in Melanoma
A Phase 3 Trial of Amezalpat in Advanced Liver Cancer Receives Study May Proceed Letter